Literature DB >> 17893575

Effect of prophylactic ondansetron on postoperative nausea and vomiting in patients on preoperative steroids undergoing craniotomy for supratentorial tumors.

Jyotsna Wig1, Kiran Nagenahalli Chandrashekharappa, Lakshmi Narayana Yaddanapudi, Dhiraj Nakra, Kanchan Kumar Mukherjee.   

Abstract

The exact incidence of postoperative nausea and vomiting (PONV) in patients on steroids undergoing neurosurgical procedures is not known. This prospective randomized double-blind study was planned to know the efficacy of prophylactic ondansetron in the prevention of PONV in patients on steroids as compared with placebo. Seventy adult patients of either sex who had received preoperative steroids (dexamethasone) for at least 24 hours and were scheduled to undergo craniotomy for supratentorial tumors were included. Patients were randomly allocated using a randomization chart to 1 of the 2 groups to receive either ondansetron 4 mg (group O) or 0.9% saline (group S) intravenously at the time of dural closure. Numeric Rating Scale score for nausea and pain intensity was recorded preoperatively and till 24 hours postoperatively. The 6-hour postoperative nausea score was significantly lower in group O [median, 0; interquartile range (IQR), 0 to 20] than in group S (median, 20; IQR, 0 to 20) (P<0.05). The incidence of vomiting was lower in group O (23%) than in group S (46%) (P<0.05). The total number of emetic episodes, the number of doses of rescue antiemetics given in the first 6 postoperative hours, and the total number of rescue antiemetics given were significantly lower in group O than in group S (P<0.05). Intravenous administration of 4 mg of ondansetron at the time of dural closure was effective in reducing the incidence of PONV and the rescue antiemetics requirement in patients on preoperative steroids undergoing craniotomy for supratentorial tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893575     DOI: 10.1097/ANA.0b013e3181557471

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  6 in total

1.  Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale.

Authors:  Bijal Surti; Brennan Spiegel; Andrew Ippoliti; Eric A Vasiliauskas; Peter Simpson; David Q Shih; Stephan R Targan; Dermot P B McGovern; Gil Y Melmed
Journal:  Dig Dis Sci       Date:  2012-12-19       Impact factor: 3.199

2.  Is microvascular decompression surgery a high risk for postoperative nausea and vomiting in patients undergoing craniotomy?

Authors:  Keita Sato; Seijyu Sai; Takehiko Adachi
Journal:  J Anesth       Date:  2013-05-07       Impact factor: 2.078

3.  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Authors:  Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

4.  Anti-emetic Drugs for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy: An Updated Systematic Review and Network Meta-Analysis.

Authors:  Yijing Chen; Jing Chang
Journal:  Front Med (Lausanne)       Date:  2020-02-25

5.  A prospective, randomized, double-blind, and multicenter trial of prophylactic effects of ramosetronon postoperative nausea and vomiting (PONV) after craniotomy: comparison with ondansetron.

Authors:  Jung-Hee Ryu; Ji-Eun Lee; Young-Jin Lim; Deok-Man Hong; Hee-Pyoung Park; Jong-In Han; Hee-Jung Baik; Hyun-Zu Kim; Kyeong-Tae Min; Sang-Hwan Do
Journal:  BMC Anesthesiol       Date:  2014-08-04       Impact factor: 2.217

Review 6.  Postoperative Nausea and Vomiting After Craniotomy: An Evidence-based Review of General Considerations, Risk Factors, and Management.

Authors:  Alberto A Uribe; Nicoleta Stoicea; Marco Echeverria-Villalobos; Alexandre B Todeschini; Alan Esparza Gutierrez; Antonia R Folea; Sergio D Bergese
Journal:  J Neurosurg Anesthesiol       Date:  2021-07-01       Impact factor: 3.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.